{
    "2021-08-17": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Lilly (LLY) Phase III Eczema Study on Lebrikizumab Meets Goal",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Phase III",
                        "Eczema",
                        "Lebrikizumab",
                        "Meets Goal"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Insulet's (PODD) Omnipod Gets FDA Nod for Use With Lyumjev",
                "features": {
                    "keywords": [
                        "Insulet",
                        "Omnipod",
                        "FDA",
                        "Lyumjev"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "medical devices"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Reorganizes",
                        "Neuroscience",
                        "Helius Medical",
                        "Breakthrough Designation",
                        "Ra Medical",
                        "Dermatology"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Eli Lilly creates neuroscience and immunology business units",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "neuroscience",
                        "immunology",
                        "business units"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Leadership Changes",
                        "Neuroscience",
                        "Immunology",
                        "Business Units"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}